According to Neurocrine Biosciences 's latest financial reports and stock price the company's current number of shares outstanding is 97,100,000. At the end of 2023 the company had 97,100,000 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Year | Shares Outstanding | Change |
---|---|---|
2023 | 97.1 M | 0.83% |
2022 | 96.3 M | 1.48% |
2021 | 94.9 M | 1.5% |
2020 | 93.5 M | 1.41% |
2019 | 92.2 M | 1.61% |
2018 | 90.74 M | 2.34% |
2017 | 88.66 M | 2.06% |
2016 | 86.87 M | 0.8% |
2015 | 86.18 M | 13.19% |
2014 | 76.13 M | 13.06% |
2013 | 67.34 M | 1.42% |
2012 | 66.4 M | 20.2% |
2011 | 55.24 M | 0.74% |
2010 | 54.84 M | 40.28% |
2009 | 39.09 M | 1.69% |
2008 | 38.44 M | 1.2% |
2007 | 37.99 M | 0.32% |
2006 | 37.86 M | 3.16% |
2005 | 36.7 M | 0.77% |
2004 | 36.42 M | 13.65% |
2003 | 32.05 M | 5.02% |
2002 | 30.52 M | 18.23% |
2001 | 25.81 M |
Company | Shares Outstanding | differencediff. | Country |
---|---|---|---|
![]() Pfizer PFE | 5,634,000,000 | 5,702.27% | ๐บ๐ธ USA |
![]() AbbVie ABBV | 1,763,968,992 | 1,716.65% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | 949,267,000 | 877.62% | ๐บ๐ธ USA |
![]() Repligen
RGEN | 55,590,000 | -42.75% | ๐บ๐ธ USA |
![]() Athersys ATHX | 18,292,000 | -81.16% | ๐บ๐ธ USA |
![]() ANI Pharmaceuticals ANIP | 16,392,000 | -83.12% | ๐บ๐ธ USA |
![]() Palatin Technologies PTN | 11,432,380 | -88.23% | ๐บ๐ธ USA |
![]() Royalty Pharma RPRX | 445,612,000 | 358.92% | ๐ฌ๐ง UK |